ESR1 and breast carcinoma: Inhibiting the mTOR-FASN axis represents a promising new strategy for treating ER/HER2-positive breast cancer; the studied combination treatment exhibited potent anti-tumor activity that may overcome resistance to endocrine therapy and HER2 inhibitors and avoid the side effects of high doses of FASN inhibitors.